A rapidly dispersible, fine-particle film-coating composition which is in powder form and is not prone to segregation for coating pharmaceutical dosage forms, consisting of a) 40-90% by weight of a polyvinyl alcohol-polyether graft copolymer (component A), b) 1-20% by weight of a polyvinylpyrrolidone or of a vinylpyrrolidone-vinyl acetate-copolymer with a K value of from 10 to 100 (component B) c) 10-60% by weight of organic or inorganic pigments having an average particle size of less than 8 μm (component C) d) 0.5-15% by weight of a surfactant having an HLB of greater than 10 (component D) and e) 0-30% by weight of further customary coating ingredients (components E),
in which the particles of component C are embedded in a coherent polymer matrix,
where the total amount of components A to E is 100% by weight.

The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.

RNA interference is provided for inhibition of HIF1A mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela associated with retinal ischemia, posterior segment neovascularization (PSNV), and neovascular glaucoma, and for treating patients at risk of developing such conditions.

Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.

Subject matter of the present invention is an anti-Adrenomedullin (ADM) antibody or an anti-Adrenomedullin antibody fragment or an anti-ADM non-Ig scaffold for use in intervention and therapy of congestion in a patient in need thereof.

The present invention provides compounds of formula (I):

##STR00001##

compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R1 to R3, R5 to R9, A, P, V, W, X, Y and Z are as defined herein.

Compositions and methods for promoting generation or regeneration of the lymphatic system in a subject are provided. Compositions and methods for the treatment of lymphedema are also provided. The composition can include extracellular vesicles and a pharmaceutically acceptable carrier, and is typically cell-free. In some embodiments, the extracellular vesicles are formed by a method including culturing MSCs to produce media conditioned with the extracellular vesicles, and optionally, but preferably separating the extracellular vesicles from the media conditioned by the MSCs. In some embodiments, the extracellular vesicles include or consist of exosomes, microvesicles or a combination thereof, and they may have a size of between about 20 nm and about 500 nm. In some embodiments, extracellular vesicles include CD9, CD63, or a combination thereof and/or one or more of miR-199a-3p, miR-145-5p, miR-143-3p, miR-377-3p, miR-100-3p, miR-29a-3p, miR-495-3p, miR-29c-3p, miR-658, miR-493-3p, miR-184, and miR-27a-3p.

The present disclosure provides methods of treating diuretic resistance by administering an IL-6 antagonist to patients who require diuresis. In typical embodiments, the patient has heart failure. Optionally, the patient has elevated urine levels of IL-6, plasma levels of IL-6, or both urine and plasma levels of IL-6.

The present invention provides compounds and compositions that inhibit Factor XIa or kallikrein and methods of using these compounds and composition.

The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.